Scarica l'app Stockscreener
25.32
1.36%
-0.32
Precedente Chiudi:
$25.64
Aprire:
$25.37
Volume 24 ore:
72,659
Relative Volume:
0.34
Capitalizzazione di mercato:
$1.69B
Reddito:
$286.00M
Utile/perdita netta:
$305.47M
Rapporto P/E:
-10.80
EPS:
-2.3434
Flusso di cassa netto:
$-492.33M
1 W Prestazione:
-9.35%
1M Prestazione:
-18.55%
6M Prestazione:
-10.89%
1 anno Prestazione:
-31.41%
Intervallo 1D:
$25.13
$25.68
Intervallo di 1 settimana:
$25.13
$27.90
Portata 52W:
$24.16
$42.45
Galapagos Nv Adr Stock (GLPG) Company Profile
Nome
Galapagos Nv Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GLPG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| GLPG | 25.34 | 1.69B | 286.00M | 305.47M | -492.33M | -2.3434 |
| VRTX | 446.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.20 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.97 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.50 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-03-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-08-24 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-11-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-08-06 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-04-20 | Iniziato | Deutsche Bank | Buy |
| 2021-04-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-02-19 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | Iniziato | Maxim Group | Buy |
| 2020-10-21 | Downgrade | Goldman | Neutral → Sell |
| 2020-08-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-08-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-08-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-07-10 | Downgrade | Stifel | Buy → Hold |
| 2020-03-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-18 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-18 | Downgrade | Citigroup | Buy → Neutral |
| 2019-12-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | Iniziato | BofA/Merrill | Neutral |
| 2019-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2019-07-31 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-29 | Downgrade | Jefferies | Buy → Hold |
Mostra tutto
Galapagos Nv Adr Borsa (GLPG) Ultime notizie
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Galapagos receives transparency notification from EcoR1 Capital - GlobeNewswire Inc.
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Belgium stocks higher at close of trade; BEL 20 up 1.37% - Investing.com
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.24% By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.32% By Investing.com - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com India
Galapagos NV shares poised for outperformance, says TD Cowen By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.79% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.79% - Investing.com India
Belgium stocks higher at close of trade; BEL 20 up 1.28% By Investing.com - Investing.com
Belgium shares higher at close of trade; BEL 20 up 1.28% - Investing.com India
Belgium stocks lower at close of trade; BEL 20 down 0.40% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.40% - Investing.com India
Adaptimmune and Galapagos partner on cancer therapy By Investing.com - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com India
Are Medical Stocks Lagging Galapagos (GLPG) This Year? - Yahoo Singapore News
Earnings call: Galapagos outlines strategic focus in Q1 2024 results By Investing.com - Investing.com
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com
Allied Gaming & Entertainment insider buys shares worth over $456,000 By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target By Investing.com - Investing.com
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA - Yahoo Finance
Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking Alpha
Galapagos Surges On New CEO and Upgrade News - Investing.com
Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs - Yahoo Finance
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves I - Benzinga
The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integr - Benzinga
Is Galapagos NV (GLPG) A Good Stock To Buy? - Insider Monkey
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares - Yahoo Finance
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes DividendAlecto - Benzinga
World’s Top-Selling Drugs: Gilead Sciences, Inc. Sovaldi Closes In On AbbVie Inc Humira - Crypto Coins Tribune
The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To DebutStaar S - Benzinga
The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOsAmarin Corp (NASDAQ:A - Benzinga
AIM tech shares that broke America - Interactive Investor
25 Stocks Moving In Friday's Pre-Market SessionAlnylam Pharmaceuticals (NASDAQ:ALNY), Aclaris Therapeu - Benzinga
Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn't Worth the Risk - InvestorPlace
Galapagos Nv Adr Azioni (GLPG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):